Literature DB >> 15725483

t(9;11)(p22;p15) with NUP98-LEDGF fusion gene in pediatric acute myeloid leukemia.

Cristina Morerio1, Maura Acquila, Cristina Rosanda, Annamaria Rapella, Elisa Tassano, Concetta Micalizzi, Claudio Panarello.   

Abstract

The rare t(9;11)(p22;p15) translocation is associated with adult acute myeloid leukemia (AML) with immature forms. We report a novel fusion of the NUP98 and LEDGF genes in a pediatric AML with intermediate characteristics between M2-M3 French-American-British (FAB) subtypes exhibiting the same chromosomal rearrangement. Fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR) studies identified the chimeric transcript product of in-frame fusion of NUP98 exon 8 to LEDGF exon 4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15725483     DOI: 10.1016/j.leukres.2004.09.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Contribution of host nucleoporin 62 in HIV-1 integrase chromatin association and viral DNA integration.

Authors:  Zhujun Ao; Kallesh Danappa Jayappa; Binchen Wang; Yingfeng Zheng; Xiaoxia Wang; Jinyu Peng; Xiaojian Yao
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 2.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

Review 3.  Virological and cellular roles of the transcriptional coactivator LEDGF/p75.

Authors:  Manuel Llano; James Morrison; Eric M Poeschla
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

4.  High-resolution profiling of the LEDGF/p75 chromatin interaction in the ENCODE region.

Authors:  Jan De Rijck; Koen Bartholomeeusen; Hugo Ceulemans; Zeger Debyser; Rik Gijsbers
Journal:  Nucleic Acids Res       Date:  2010-05-19       Impact factor: 16.971

5.  Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75.

Authors:  Terry A Brown-Bryan; Lai S Leoh; Vidya Ganapathy; Fabio J Pacheco; Melanie Mediavilla-Varela; Maria Filippova; Thomas A Linkhart; Rik Gijsbers; Zeger Debyser; Carlos A Casiano
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

6.  The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.

Authors:  Marcelo J Murai; Jonathan Pollock; Shihan He; Hongzhi Miao; Trupta Purohit; Adam Yokom; Jay L Hess; Andrew G Muntean; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113

7.  Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75.

Authors:  Batya Cohen; Yoseph Addadi; Stav Sapoznik; Gila Meir; Vyacheslav Kalchenko; Alon Harmelin; Shifra Ben-Dor; Michal Neeman
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

8.  Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types.

Authors:  Anamika Basu; Heather Rojas; Hiya Banerjee; Irena B Cabrera; Kayla Y Perez; Marino De León; Carlos A Casiano
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

9.  Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of PogZ.

Authors:  Koen Bartholomeeusen; Frauke Christ; Jelle Hendrix; Jean-Christophe Rain; Stéphane Emiliani; Richard Benarous; Zeger Debyser; Rik Gijsbers; Jan De Rijck
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.486

10.  LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Authors:  Tien-sheng Huang; Line M Myklebust; Endre Kjarland; Bjørn Tore Gjertsen; Frederic Pendino; Øystein Bruserud; Stein Ove Døskeland; Johan R Lillehaug
Journal:  Mol Cancer       Date:  2007-04-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.